AbCellera Biologics Inc (NASDAQ: ABCL) Investors To Make Big Returns Again

In the last trading session, 17.47 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.38. With the company’s per share price at $3.02 changed hands at $0.51 or 20.32% during last session, the market valuation stood at $901.43M. ABCL’s last price was a discount, traded about -21.85% off its 52-week high of $3.68. The share price had its 52-week low at $1.89, which suggests the last value was 37.42% up since then.

Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.16.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Instantly ABCL was in green as seen at the end of in last trading. With action 30.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.07%, with the 5-day performance at 30.74% in the green. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is 48.77% up.

The consensus price target for the stock as assigned by Wall Street analysts is 23.5, meaning bulls need an upside of 87.15% from its current market value. According to analyst projections, ABCL’s forecast low is 5 with 34 as the target high. To hit the forecast high, the stock’s price needs a -1025.83% plunge from its current level, while the stock would need to soar -65.56% for it to hit the projected low.

AbCellera Biologics Inc (ABCL) estimates and forecasts

Year-over-year growth is forecast to reach -9.62% down from the last financial year.

Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.55M. 9 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 7.57M. The company’s revenue for the corresponding quarters a year ago was 7.32M and 6.51M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3.04%. The estimates for the next quarter sales put growth at 16.35%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -107.74%. The 2025 estimates are for AbCellera Biologics Inc earnings to decrease by -10.77%, but the outlook for the next 5-year period is at 0.83% per year.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were SMALLCAP WORLD FUND INC and iShares Trust-iShares Biotechnology ETF. With 13.36 shares estimated at $40.35 million under it, the former controlled 4.48% of total outstanding shares. On the other hand, iShares Trust-iShares Biotechnology ETF held about 0.48% of the shares, roughly 1.42 shares worth around $4.28 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.